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Abstract 
Following discoveries about the role that human basic fibroblast growth factor (bFGF or 
FGF-2) plays in cell reprogramming events, this project endeavored to establish a mammalian cell 
platform for further study of these proteins and their functions. FGF2 is encoded by a single mRNA , 
which utilizes the discrete 5’ start sites resulting in production of five FGF2  protein isoforms; a low 
molecular weight (18kDa) isoform that is ligand for the plasma membrane FGF tyrosine kinase 
receptors and four high molecular weight isoforms (22, 22.5, 24 and 34 kDa) that regulate cell 
function via nuclear-mediated actions. The five isoform sequences were originally cloned into 
separate pBluescript vectors. The sequences were then subcloned into a mammalian expression 
vector, and the protein was overexpressed in CHO-K1 cells where production and localization were 
verified by immunoblotting. We report production of two of the five protein isoforms as 
recombinant human proteins. 
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Background 
1.1 Introduction 
The Fibroblast Growth Factor (FGF) family of growth factors is comprised of several 
different genes, all of which bind as ligands to FGF tyrosine kinase receptors.  This family of 
proteins was first identified in 1973 in pituitary extracts (Armelin, 1973), and later it was observed 
that this same protein extracted from a cow brain caused 3T3 fibroblasts to proliferate in a 
bioassay (Gospodarowicz, 1974). This type of activity was later related to an observation from 
1939, that the brain was an area with a high occurrence of fibroblast mitogenic activity. It was 
found that FGF when separated by isoelectric points fell into two major peaks: one acidic and one 
basic. These were then dubbed Acidic FGF (aFGF or FGF-1), and Basic FGF (bFGF or FGF-2) 
(Thomas, 1987).  Since that point, there have been 22 FGF genes identified, which are dispersed 
throughout the genome in small clusters. Some FGFs even have multiple active loci, such as FGF-7 
which has active segments in 16 locations throughout the genome (Ornitz and Itoh, 2001; Kelley et 
al., 1992). These facts support the idea that there have been both gene and chromosomal 
replication and translocation over the course of time (Ornitz and Itoh, 2001). These genes gain even 
more variable structures and functions via alternative splicing and internal ribosomal entry sites 
(IRES). FGF-2 and FGF-3 exhibit IRES activity, which utilizes 5’ CUG alternative initiation sites to 
create 5’ extensions of the protein (Keifer et al., 1994; Arnaud et al., 1999). Other FGFs also use sub-
exon splicing to allow further varieties of the protein to be created (Ornitz and Itoh, 2001). The 
coding section of the DNA is typically comprised of 3 exons where exon 1 contains the translational 
start methionine; however there are notable exceptions, such as the FGFs with 5’ CUG initiation 
sites. Fibroblast Growth Factors typically have a recognizable amino terminal secretion sequence, 
which means that they act in an exocrine-like manner. FGFs 9 (Miyake et al, 1998), 16 (Miyamoto et 
al., 1993), and 20 (Ohmachi et al., 2000) all lack known amino-terminal secretion signals, yet are 
secreted from the cell normally. FGFs 1 and 2 also lack an amino-terminal secretion signal, (with 
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the exception of the 18kDa FGF-2 Isoform) instead they have nuclear localization signals (Ornitz 
and Itoh, 2001). All of the various FGFs are expressed at different times throughout an organism’s 
life cycle, and while some (FGF3,4,8,15,17,and 19) are expressed solely in the developmental stages, 
others seem to be expressed throughout the entire lifespan (FGF1,2,5,6,7,9-14,16,18, and 20-23) 
(Ornitz and Itoh, 2001). It has been shown by creating knockout animals that many different 
phenotypes can be observed by deleting single FGFs: some are immediately lethal (killing the 
animal before birth), while others have very subtle phenotypes (Ornitz and Itoh, 2001). The 
appearance of subtle non-fatal phenotypes is thought to arise because FGFs have similar and 
overlapping functions, and thus deletion of one could possibly be compensated for by another 
similar FGF. Overall, these genes and their protein products seem to play a fairly diverse role in the 
developmental stages of life, but based on many methods of regulation: alternative splicing, 
alternative initiation, secretion, and specificity.  These proteins are capable of being tightly 
regulated, in order to prevent uncontrollable growth or another deleterious phenotype. 
1.2 FGF-2 
Basic Fibroblast Growth Factor 2 (bFGF-2 or FGF-2) was first discovered as a 146-amino 
acid protein that was isolated from the pituitary gland (Bohlen, et al., 1984).  FGF-2 cDNAs were 
cloned and the start codon (AUG) was located in the place to begin translation of a 155 amino acid 
protein (Abraham, et al., 1986).  Also, there was no in-frame start codons found upstream, so the 
aforementioned start codon is the predicted start site for translation (Abraham et al., 1986).  On the 
other hand, FGF-2 proteins come in a variety of lengths, both shorter and longer than the predicted 
length from the cDNA sequence (Florkiewicz, et al., 1989).  The longer or higher molecular weight 
proteins (196, 201, and 210 amino acids) were found to be created through in vitro transcription 
and translation analysis.  This revealed that CUG codons were used as the translation start site for 
these larger segments (Prats, et al.,1989).  The shorter proteins were found to be from the result of 
proteolytic degradation (Klagsbrun, et al.,. 1987).  
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 Other translation happens by internal ribosomal entry sites in the FGF-2 mRNA (Vagner, et 
al., 1995).  When the single FGF-2 cDNA is expressed in cells, a single AUG and three CUG start 
codons were observed (Figure 1) (Quarto et al., 1991).  The 22, 22.5, and 24 kDa sizes of the protein 
are initiated at the CUG start codon (Quarto et al., 1991).  The 18 kDa protein is initiated at the AUG 
start codon, which is farther downstream.  This explains why the 18 kDa protein is so much smaller 
than the others (Quarto, et al.,  1991).  More recently it was determined that the 34 kDa isoform has 
a CUG start codon that is located 86 nucleotides away from the FGF-2 mRNA 5’ end (Arnaud et al., 
1999).  Also, the 22, 22.5, and 24 kDa sizes of the protein are largely localized in the nucleus, while 
the 18 kDa size is localized in the cytoplasm (Bugler, et al,. 1991).  
 
A three-dimensional crystalline structure of 18 kDa FGF-2 has been created through the use 
of recombinant proteins (Ericksson, et al., 1991).  FGF-2 includes 12 anti-parallel beta sheets that 
are organized into a trigonal pyramidal structure (Zhu et al., 1991).  The receptor binding sites are 
believed to be residues 13 to 30 and 106 to 129 (Baird et al., 1988).  There are also two potential 
phosphorylation sites, serine 64 and threonine 112.  Protein kinase A and protein kinase C are 
responsible for the phosphorylation of FGF-2, and they may be localized in the nucleus and at the 
cell surface (Feige and Baird, 1989).  
Fig 1:  mRNA coding schematics of the five FGF-2 
isoforms with start codons for each iosform (Atlas of 
Genetics). 
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 A distinctive feature of the high molecular weight isoforms of FGF-2 is the amino terminal 
extension.  The largest isoforms has a nine glycine – arginine reiterations (Quarto et al., 1991). 
1.3 Cell Proliferation  
FGF-2 has been shown to stimulate cell proliferation in an immature dental pulp cell model.  
These cells were isolated from mandibular incisors in rats.  The cells were exposed to BMP-2, BMP-
4, FGF-2, FGF-8, and NGF treatments and assayed from cell proliferation at four days in culture.  Of 
the five treatments, FGF-2 yielded significantly higher proliferation.  The treatments were 
performed a second time but with the use of β-Glycerophosphate, which is thought to induce 
growth in this cell type.  The second treatment increased proliferation in all five samples but FGF-2 
was still the only one to show significant increases in proliferation.  Not only is FGF-2 effective in 
stimulating cell proliferation across varying cells types, it also can be paired with specific inducers 
to improve effectiveness (Nakao et al,. 2004). 
1.4 Cell Migration 
Cell migration requires all cells to be properly directed to specific locations.  FGF-2 has been 
shown to play a crucial role in this function in certain functions, particularly in myelantation of the 
central nervous system (CNS).  Oligodendrocyte precursors differentiate into the myelin-forming 
oligodendrocytes in the CNS.  These cells originate at a specific location in the neural tube; 
therefore they must undergo migration to populate the entire CNS.  One study showed that in the 
presence of FGF-2 cells underwent movement, but once FGF-2 was removed from the culture 
medium or FGF receptors were blocked, movement almost immediately stopped (Bribian, et. al., 
2006).   
1.5 Early Embryonic Differentiation 
The process by which a fertilized egg changes into a fully developed organism is known as 
differentiation.  This is when the mass of totipotent cells differentiates into highly specified cells in 
the body (i.e. skin or bone cells).  Totipotent cells are cells that have the ability to become any other 
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cell, unlike a cell that is hematopoietic, which can only differentiate into a blood cell.   The main 
mystery surrounding totipotent cells is how they organize themselves into an embryo with a dorsal 
and a ventral side.  Studies have shown that just before differentiation occurs, proteins can 
segregate themselves toward what will be the frontal and posterior ends of the embryo.  A better 
understanding of these processes could lead to greater successes with in-vitro fertilization.  Also, 
this process could in theory be used to make a cell revert to a state of higher potency and can thus 
be used for clinical research.  Due to cells dependence on FGF-2 to maintain pluripotency FGF-2 
could potentially play a role in steps of embryonic differentiation. (Said, et al., 2010) 
1.6 Neuronal development 
FGF-2 has been implicated in a variety of functions in the body, one of which is 
neurological development. Studies into these functions have yielded a great deal of information that 
may lead to some potential research avenues and therapies for various disorders. A prime example 
of this is a study from 2000, which presented a potential treatment to slow the rate of retinal 
degeneration due to retinitis pigmentosa, a type of eye disease leading to incurable blindness. In the 
study, transgenic rats were injected with an adenovirus containing the FGF-2 gene. These rats 
presented with a decreased rate of photoreceptor degeneration, as well as a slight increase in 
electroretinographic (ERG) responses, an electrical response in various parts of the eye, such as 
rods and cones. However, these ERG responses were not a significant improvement over the ERG 
responses from rats given an adenovirus without the FGF-2 treatment (Lau, et al., 2000). 
With regards to neurological function, FGF-2 is considered essential to developing the 
central nervous system. Studies have shown that in murine embryos, FGF-2 is found at high levels 
during neurulation, an early developmental stage of nervous system formation in utero. In addition, 
overexpression of specific FGF-2 isoforms has been implicated in regulating growth during spinal 
cord development. In an article from 1998 entitled “Impaired cerebral cortex development and 
blood pressure regulation in FGF-2-deficient mice”, scientists at the University of Heidelberg noted 
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that mice that lacked expression of FGF-2 resulted in widespread neuronal defects in the cerebral 
cortex, spinal cord, and hippocampal commissure, which is a part of the hippocampus that connects 
the other sections (Dono, et al., 1998). All of this data suggests that FGF-2 is an integral protein in 
pre-natal nervous system development. 
            FGF-2’s functions in the nervous system are also prevalent in fully developed organisms. 
FGF isoforms are found in astrocytes in the brain, which are necessary for healthy brain function 
and the regeneration of neurons, among other vital biochemical processes in the brain. FGF-2’s 
specific function in these cells is to regulate levels of glial fibrillary acidic protein (GFAP), which is 
found in gray matter astrocytes. A study into FGF-2-/- single and FGF-2-/--FGF-5-/- mutants showed 
that FGF-2 is required for these astrocytes to differentiate. The most important finding from this 
study, however, is that FGF-2 plays a role in maintaining the blood brain barrier via GFAP and 
astrocytes. All of this information provides a strong foundation for understanding FGF-2’s role in 
neurology, and a greater understanding of these FGF-2-associated pathways could lead to novel 
therapies for neurological disorders, as well as a potential way to repair some forms of brain 
damage (Reuss, et al., 2003). 
1.7 Angiogenesis 
            Although FGF-2 has a definitive link to the nervous system, one of the growth factor’s major 
features is its ability to promote the growth of blood vessels, a process known as angiogenesis. In a 
study comparing murine blood vessels grown using FGF-2, vascular endothelial growth factor 
(VEGF)-A, and VEGF-C, it was found that FGF-2-based blood vessels had little or no vascular 
fenestrations, or openings in blood vessels allowing for rapid exchange of fluids between the 
circulatory system and surrounding tissues. In contrast, VEGF-A blood vessels were found to be 
highly fenestrated. This finding would suggest that FGF-2-based angiogenesis could be a potential 
method of creating blood vessels for vital organs. While scientists do not currently understand how 
exactly FGF-2 regulates angiogenesis, FGF-2 is currently undergoing clinical trials as a treatment for 
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ischemic heart disease (Cao et al.,. 2004). 
           In yet another role, FGF-2 has been shown to have the ability to induce hypotension in 
animals (Cuevas et al., 1991), as well as hypertension under certain incidents of cellular stress.  In 
the 1998 article from the University of Heidelberg, the FGF-2-deficient mice that were studied 
showed a lower than normal blood pressure, in addition to neuronal defects. However, subsequent 
tests on the cardiovascular system showed responsiveness, with the exception of an impaired 
baroreceptor reflex (Dono et al., 1998). This led scientists to believe that the problem was coming 
from a dysfunctional autonomic nervous system, since the mice were already suffering various 
neurological defects, and baroreceptor reflexes are governed by the nervous system. 
1.8 Regeneration and Stem Cell Pluripotency 
The range of processes FGF-2 affects allows it to be applied to a variety of applications in 
research.  Many recent discoveries for the applications of FGF-2 include bone healing, tissue 
regeneration, and maintenance of pluripotency.  A clinical study running from 2006-2007 looked at 
alveolar bone height regeneration as affected by application of FGF-2.  Patients suffered from 2- or 
3-walled intrabony defects and were assigned to four groups, each receiving a separate treatment 
including controls and increasing dosage of recombinant FGF-2.  The treatments were delivered 
during periodontal surgery to affected sites.  The results showed major rate increases in 
regeneration between the control group receiving surgery with no FGF-2 administered and the 
group with the highest concentration of FGF-2 (Fujii, et al., 2010).  This result was one of many 
being discovered through the use of FGF-2 to restore bone and tissue mass.  An even larger study 
published in 2010 yielded the same results, stating a percentage of bone fill, up to 69.14% 
(Kitamura, et al., 2010).  Bone fill is defined as the increase in alveolar bone height.  FGF-2’s 
stimulation of proliferation and pluripotenncy maintenance, as well as angiogenesis (Shimabukura 
et al., 2005) and stimulation of other extracellular matrix production, created an environment for 
tissue regeneration to occur (Terashima et al., 2005). 
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1.9 Maintenance of Stem Cell Pluripotency 
The application of FGF-2 to stem cell growth media allows cells to maintain their 
pluripotent state.  In a 2005 study, human embryonic stem cells were grown at concentrations of 
40ng/ml and 100ng/ml FGF-2.  At 40ng/ml ES cells were maintained with consistent centers of 
differentiation in the colonies; at 100ng/ml these centers were prevented.  Cells cultured in 
100ng/ml were maintained for 4-7 months and then successfully analyzed for OCT4 and NANOG, 
markers for undifferentiated cells.  Later it was determined that expression of OCT4, SOX2, and 
NANOG all promote increased expression of FGF-2, creating a regulatory loop to maintain the 
pluripotent state (Levenstein et al., 2006). 
1.10 Osteogenesis 
FGF-2 also can be used to increase bone-healing capacity in different parts of the body.  The 
skull’s frontal bone has been shown to possess great healing capacity and a highly activated FGF-
domain.  By exposing the less active parietal bone to FGF-2 it is able to mimic the superior healing 
of the frontal bone.  After drilling holes in frontal and parietal skull bone of mice they were treated 
with FGF-2 soaked collagen sponges and monitored for FGF signaling and proliferation markers. 
 After exposure to FGF-2, the parietal bone displayed increased bone regeneration, cell 
proliferation, and osteogenic progenitors as well as activated FGF-2 signaling pathways.  The use of 
exogenous FGF-2 shows the ability to overcome pre-determined bone healing properties (Behr et 
al., 2009). 
1.11 Preserving organ viability 
As well as possessing regenerative properties, FGF-2 has also been used as a supplement in 
serum-free media for storage of human and porcine corneas.  Currently corneas are stored in fetal 
calf serum, but this has adverse effects due to bovine-related disease concerns and the inability to 
repeatedly produce standardized media.  By using a serum-free media supplemented with FGF-2, 
the endothelial survival of corneas has a significant survival increase.  Serum-free media 
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supplemented with FGF-2 yielded a reduced amount of damaged endothelial cells occurring over 
nine days of storage.  After 22 days of storage, FGF-2 supplemented media still maintained a 
reduced damaged state.  FGF-2 media also contained less apoptotic and dead cells, consistent with 
the effects of fetal calf serum and significantly better than serum-free media without FGF-2.  The 
effect of FGF-2 in this media is purely protective; it prevents damage and death but was not shown 
to stimulate mitosis.  It is an important contributor to improving organ storage and a viable 
alternative to serum based media (Rieck et al,. 2003). 
1.12 Cloning and Expression of Human Recombinant FGF-2 Isoforms 
With the discovery of the myriad of implications FGF2 has in the body, it has become 
prudent that this protein family be studied in depth. However, studying these proteins individually 
is hampered by the fact that they are all translated from the same mRNA. In this project, each of the 
unique isoforms were attempted to be cloned into separate recombinant expression vectors, as well 
as transfected into mammalian cell cultures to ensure recombinant protein production.  In this 
project mammalian expression vectors for 22.5, 24, and 34 kDa isoforms were created and protein 
production of 22.5 kDa and 34 kDa isoforms was verified in CHO-K1 cells.  
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Results 
 2.1 Subcloning Plan 
  This project began with all 5 isoforms of FGF-2 (18, 22, 22.5, 24, 34 kDa) contained within 
individual pBlueScript bacterial vectors. The protein encoded in these sequences consisted of the 
full-length mature protein with a 6xHis-Tag at the N Terminus and a TEV protease cleavage site 
between that and the mature protein sequence. It was determined that the best way to express the 
FGF-2 isoforms in a useful way was to subclone the sequence into a mammalian expression vector 
directionally (Figure 2).  The sequence contained EcoRI and Hind III restriction sites usable in the 
subcloning method.  After pBS digestion with EcoRI and HindIII, the insert sequence, complete with 
6xHis tag, TEV protease site, and sticky ends, would be recovered.  This insert would then be ligated 
into the similarly digested mammalian expression vector pcDNA3.1(-) (Invitrogen).  This ligation 
would yield a recombinant ligation product of pcDNA3.1(-) + FGF-2 with proper directionality. 
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2.2 Isolation of Recombinant Isoform Specific cDNA 
The initially supplied pBS vectors with FGF-2 (18, 22, 22.5, or 34 kDa) were digested with 
EcoRI and HindIII to cleave out the gene contained each vector’s respective MCS (Figure 3).  The 
digestions were then run on a 1% agarose gel.  Each gel then had a band extraction and purification 
performed to recover the coding insert of each isoform in preparation for ligation into a 
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mammalian expression vector.  The concentrations recovered from each extraction were:  18kDa - 
60ng/µl, 22kDa - 23ng/µl, 22.5kDa - 25ng/µl, 24kDa – 23ng/µl, 34kDa – 59.9ng/µl. 
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Each pBS vector, cut with EcoRI and HindIII, was then run on a single 1% agarose gel in 
order to demonstrate the increase in size of each isoform’s coding region.  Due to gel smiling, the 
migration of the bands was altered but the size differences are still apparent (Figure 4). 
 
2.3 Isolation of pcDNA3.1(-) Linearized Vector 
After each isoform’s insert was isolated and extracted from its pBS vector, it was necessary 
to ligate the insert into pcDNA3.1(-) as described in the subcloning method.  In order to maximize 
use of materials pcDNA3.1 (-) was transformed into DH5α.  The vector contains the gene for 
ampicillin resistance, therefore transformed DH5α was grown under the selective pressure of 
ampicillin.  These liquid cultures were then miniprepped to extract the plasmid.  The purified 
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plasmid was then prepared for ligation by digestion with EcoRI and HindIII in order to maintain 
directionality for insertion (Figure 5). 
 
 
2.4 Creation of Mammalian Expression Vector 
Once both the insert and vector had been digested and gel extracted, they were ligated and 
subsequently transformed into chemically competent DH5α. Colonies which grew on an antibiotic-
containing LB+agar plate were liquid cultured, and their plasmid was miniprepped. The extracted 
plasmid was double-digested with EcoRI and HindIII to ensure the identity of the plasmid the 
transformants contained (Figures 6, 7, 8).  
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2.5 Protein Production in Mammalian Cells 
After the recombinant plasmid was generated, its identity and functionality needed to be 
tested. This was achieved by transfecting the plasmid into an easily transfectable mammalian cell 
line: CHO-K1 to be specific. After 3 days of being incubated with the lipid transfection reagent and 
recombinant plasmid, protein production was tested for by immunoblotting lysates from selected 
treatments (Figure 9. The ratios refer to μg plasmid: μL Transfection reagent).  
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After the transient transfections were tested, the cells were kept under antibiotic selection and 
were eventually immunoblotted again to verify the presence of His-tagged protein being 
constitutively expressed in all samples. This immunoblot for stable transfection was performed on 
both the 22.5kDa and 34kDa isoforms of recombinant FGF-2(Figures 10 and 11, respectively).  
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After constitutive overexpression of the proteins was confirmed, it was decided to begin 
performing loading controls and probe with alternative antibodies (Figure 11) such as Anti-FGF-2 
antibody.  Anti-Actin was used as a loading control to ensure that all lanes were loaded equally.  
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2.6 Enrichment of Recombinant FGF-2 via Nickel Column Enrichment 
A nickel resin was used to preferably associate with the 6xHis tagged region of the protein, 
and then the resin was washed, and eventually the proteins associated with the resin were eluted 
by introducing increasing concentrations of imidazole to the buffers used. Imidazole competes for 
binding to the nickel in the resin, allowing for the proteins to be collected in the elution. The 
resulting fractions were immunoblotted to observe their purity (Figure 12). 
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Discussion 
  The five pBluescript constructs containing cDNA for each individual FGF-2 isoform (18, 22, 
22.5, 24, 34kDa) were successfully amplified under ampicillin antibiotics in E. coli and then isolated.  
The isolated vectors were digested with EcoRI and HindIII and from the digest we were able to 
isolate the FGF-2 cDNA from the vectors.  The isolated inserts were then ligated into pcDNA3.1(-).  
The 22.5, 24, and 34kDa cDNA were successfully ligated in the vector and amplified in E. coli under 
ampicillin selection.  This was confirmed by restriction enzyme double digest and gel 
electrophoresis.  We attempted to ligate the 18kDa and 22kDa isoform cDNA into the mammalian 
expression vector but transformation with the ligation reaction yielded no transformant colonies.   
Only the completed 22.5 kDa and 34 kDa mammalian expression vectors were transfected 
into mammalian CHO-K1 cells.  The transfection was performed using a lipid transfection reagent.  
Initially the cells were allowed to grow without antibiotics to allow the transfection reagent and 
vectors to be fully incorporated, but after three days the antibiotic G418 was added.  This allowed 
for selection of only cells which were expressing neomycin resistance (signaling vector integration).  
The cells were cultured for three weeks at varying concentrations of antibiotics, proving that the 
cells had correctly taken up our genes of interest. 
 In immunoblots of stably transfected CHO-K1 cells, the expression of 22.5 and 34 kDa FGF-2 
isoforms were examined.  Whole cell fractions and soluble fractions of both cell lines were probed 
using anti-FGF-2 and anti-6xHis.  CHO-K1Probing with each of these antibodies had a separate goal 
in the experiment of determining correct plasmid function. The anti-actin was to ensure that all 
lanes were loaded with an equal amount of protein so that all lanes were comparable to each other. 
The anti-his was to show whether recombinant protein was being produced, since wild type protein 
does not have a 6xHis tag. Finally, the anti-FGF2 was to see whether CHO-K1 cells endogenously 
produce FGF-2, and if this was the case to see whether plasmid treatment resulted in 
overexpression.  
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 Part of this project’s goal was to establish a mammalian cell platform for expression of 
individual isoforms.  In order for this to be successful on a larger scale proper purification 
techniques must be established.  Through nickel column enrichment we were able to show that the 
6xHis tag is functional in a purification scenario.  The enrichment of the 22.5 kDa isoform shows 
that the recombinant protein binds tightly to the resin because of the lack of FGF-2 in the flow-
though. This enrichment also shows that the protein has a fairly high affinity for the resin, since 
during the various wash steps, no protein was eluted. As higher concentrations of imidazole are 
added to the resin the imidazole competes for binding, releasing the isoform from the column for 
collection.  The successful protein enrichment suggests that a larger scale purification with a full 
column would result in protein purification rather than enrichment due to the larger concentration 
of recombinant protein as well as ability to be more specific with elution buffer concentrations. 
 The purpose of this project was to create a base for more study.  Continuations of this 
project would absolutely include creation of the 18 kDa and 22 kDa mammalian expression vectors 
as well as transfection of the remaining vectors into CHO-K1 cells and validation of protein 
production.  Additionally, transfection into a primary cell line (Fibroblasts) would allow for various 
immunoprecipitation assays to determine protein binding information such as chromatin 
immunoprecipitation (ChIP) and protein complex immunoprecipitation (Co-IP).  Studies could also 
be done to examine exogenous activation of known membrane proteins (FGFR1) and protein 
localization.  The range of activities associated with FGF-2 creates an even broader range of 
research venues for this protein.  Once the actions of the individual isoforms can be identified 
therapy and research currently being done with FGF-2 may be significantly improved. 
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Materials and Methods 
Vectors Used 
The two vectors used included pBluescript (figure 13) and pcDNA3.1 (figure 14).  
pBluescript contains the ampicillin resistance gene and a lacZ gene.  The lacZ gene was used as a 
reporter for proper ligation into the MCS.  pcDNA 3.1(-) from Invitrogen was selected as the 
mammalian expression vector because of its strong CMV promoter and MCS orientation, as well as 
ampicillin and neomycin resistance genes used for bacterial and mammalian growth selection. 
 
Cell culture 
For propagation of the plasmid DNA for the subcloning process, the DH5α strain of E. coli 
was used. These were grown in LB or SOC Media, or on LB or SOC agar plates. Ampicillin was used 
in the media and agar to select for E. coli which contained the DNA of interest.  The mammalian cell 
line used was the adherent CHO-K1 line. The CHO-K1 cells were grown in 50% DMEM/50% Ham’s 
F-12 (D/F12), with varying concentrations of FBS (between 5 and 10%). Initially no antibiotics 
were used, but after transfections, G418 was used to select for transfected cells. Varying 
concentrations were used: 500μg/mL and 750μg/mL for transfections, and 100μg/mL for 
maintaining selection after protein production was confirmed.  
Vector Construction 
In order to construct the pcDNA3.1(-) mammalian expression vector, the directionality of 
the insertion was considered a top priority. Both the vector and gene of interest containing 
bacterial vector were digested with EcoRI and HindIII from NEBiolabs. These digests were analyzed 
 
Fig 13:  pBluescript schematic detailing origins of 
replication, ampicillin resistance gene, lacZ, and 
the multiple cloning sites. 
 
Fig 14:  pcDNA3.1 (+/-) schematic detailing 
promoters, origin of replications, ampicillin, 
and neomycin resistance. 
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by gel electrophoresis on a 1% agarose gel in 1xTAE.  The fragment was then ligated using the 
Fermentas Rapid DNA Ligation Kit following manufacturer directions. The resulting reaction was 
transformed into competent DH5α (Either NEBiolabs NEB5-α or Inoue competent cells). These 
were then plated on appropriate plates containing 50μg/mL of ampicillin. 
Restriction Digest 
Restriction digests were performed by combining the following into a PCR tube: 1µg of DNA, 
1 µl EcoR1, 1 µL HindIII, 1 µl BSA, 1/10 final volume NEB Bufferx2, and DNA quality water 
(NEBiolabs) to adjust final volumes as needed.  The reaction was then allowed to occur over 60 
minutes at 37°C and sizes of restriction fragments verified by agarose gel electrophoresis. 
Competent Cells 
Competent cells used were NEB5α (New England Biolabs) and Inuoe competent cells.  Inuoe 
competent cells were prepared according to the protocol outlined on pages 1.112-1.114 of 
Molecular Cloning: A Laboratory Manual, Volume 1 (Sambrook, et al.. 1989). 
Transient and Stable Transfections of CHO-K1 
The transient and stable transfections were started in a 6 well plate with 9.6x104 cells per 
well, and when they were between 50-90% confluent, transfection was performed with Biorad 
Transfectin lipid transfection reagent according to the manufacturer’s protocol, except that the final 
volume of serum free media used per well was 100μL. The cells were left in the transfection media 
for 3 days and one well of each treatment was harvested, lysed and immunoblotted as described 
below. The remaining wells had the media replaced, and then were split into additional wells, and 
500μg/mL G418 was used to select for transfected cells. After 2 weeks of selection at this level, half 
of each treatment remained under 500μg/mL G418 treatment, while the other half was increased to 
750μg/mL G418. After the third week of antibiotic selection, one well of each treatment was 
transferred into a 10cm tissue culture dish. These were used to continue the treatments, and to 
create cells for analysis. After verification of protein production, the antibiotic treatment was 
reduced to 100μg/mL G418 to maintain the lines.   
Preparation of cell lysates and Immunoblotting 
Whole cell fractions were prepared via 3 rounds of 10 bursts of sonication on low power 
(because the pellets were small). The soluble fraction was prepared by centrifuging the whole cell 
fraction at max RCF of the centrifuge for 15 minutes, and then sampling the clarified supernatant. 
Samples of these two fractions were combined with 4:1 with 5xBME protein loading buffer.  
Samples were loaded into a 15% SDS acrylamide gel, electrophoresed at 170V in Tris-glycine 
running buffer (0.025M Tris 0.2 M Glycine + 1% SDS) using Fermentas PAGE Ruler as a size marker. 
The proteins were transferred to a PVDF membrane in a semi-dry electrophoretic transfer cell 
using Towbin transfer buffer (0.025M Tris 0.2M Glycine buffer with 20% methanol). The 
membrane was blocked using 5% milk in Tris Buffered Saline(0.14M NaCl, 3mM KCl, 0.025M Tris 
Base) +0.1% Tween (TBST). The membrane was then incubated overnight with the primary 
antibody (Anti-His from Clontech (1:5000 dilution), Anti-Actin from Sigma (1: 5000), or Anti-FGF2 
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from AbCam (1:1000)) with rotation at 4oC. The following day the membrane was washed in TBST 
and then incubated for 1.5-2hrs with the alkaline phosphatase-conjugated secondary antibody: 
anti-rabbit, anti-mouse, or anti-goat (all at a 1:5000 Dilution, and all from Abcam). The membrane 
was washed again first with TBST and then with diH2O, and incubated with AP substrate. The color-
producing reaction was stopped by immersing the membrane back in the diH2O prior to 
visualization. Chemmilluminescence images were acquired using Kodak 4000MM imager. 
Nickel Resin Enrichment 
 Nickel resin (General Electric) was used to enrich samples of the recombinant protein from 
soluble fractions isolated from the transgenic CHO-K1 cells. The soluble fraction was incubated with 
250 μL of equilibrated nickel resin (because a small scale protocol was used), and then was washed 
and treated with various concentrations of imidazole which competes with his-tagged proteins to 
bind to the nickel resin. These elutions were collected, and then were subsequently immunoblotted 
using an anti-6xhis antibody as the primary antibody.  
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